Libero Santarpia

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

42h-index7.1kcitations165works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(45), Circular RNAs in diseases(31), Cancer-related molecular mechanisms research(26), HER2/EGFR in Cancer Research(25), Cancer Genomics and Diagnostics(18)

Publications165 total

Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes
The Oncologist·2025· 1 citedOpen Access
CancerHallmarks.com: A tool for the enrichment analysis of the cancer hallmarks.
Journal of Clinical Oncology·2024
Abstract PO2-03-08: Uncovering Novel Potential Prognostic Biomarkers in Basal-Like Breast Cancer using Transcriptomic Data of 1,899 Patients
Cancer Research·2024
Abstract PO2-03-07: Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer
Cancer Research·2024
Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
International Journal of Molecular Sciences·2023· 40 citedOpen Access
Supplementary Table S2 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Table S3 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Table S1 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Data from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Table S3 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figures Legends from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Table S1 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Data from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figure S1 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figures Legends from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figure S3 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Table S2 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figure S2 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figure S3 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
Supplementary Figure S1 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Giulia Bottai(15), Lajos Pusztai(10), Balázs Győrffy(9), Angelo Di Leo(8), Adel K. El‐Naggar(6), George A. Călin(5), Takayuki Iwamoto(5), Giampaolo Bianchini(5), W. Fraser Symmans(5), Francesco Trimarchi(5), Yuan Qi(4), Gabriel N. Hortobágyi(4), Steven I. Sherman(4), Robert F. Gagel(4), Gyöngyi Munkácsy(3), Erica Moretti(3), Fabrice André(3), Laura Paladini(3), Carlotta Raschioni(3), Jorge S. Reis‐Filho(3)